Login to Your Account



Neurologix, Celladon, Then . . . ?

Phase II Gene-Therapy Wins: Father, Son Harvest Research

By Randy Osborne


Monday, June 28, 2010
Neurologix Inc.'s Phase II victory last week with NLX-P101 brought a much-needed credibility boost for gene therapy in Parkinson's disease and closely followed good news at the same clinical stage in advanced heart failure from Celladon Corp. with partner Targeted Genetics Corp.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription